Xiao Bin Wu

General Manager, China & President at BeiGene Ltd.

Xiao Bin Wu

Xiao Bin Wu

General Manager, China & President at BeiGene Ltd.

Biography

Currently, Xiao Bin Wu holds the position of President & General Manager-China Region at BeiGene Ltd. and Chairman & Manager at BeiGene (Guangzhou) Co., Ltd. and Chairman of BeiGene Pharmaceuticals (Guangzhou) Co., Ltd. (both are subsidiaries of BeiGene Ltd.). He is also Country Manager-China at Pfizer Pharmaceuticals Ltd. He received a doctorate and a graduate degree from Universität Konstanz.

Overview

RelSci Relationships

946

Birthday

1962

Age

59

Relationships

View Relationship Details

RelSci Relationships are individuals Xiao Bin Wu likely has professional access to. A relationship does not necessarily indicate a personal connection.

John V. Oyler

Co-Founder at BeiGene Ltd.

Relationship likelihood: Strong

Xiaodong Wang

Co-Founder at BeiGene Ltd.

Relationship likelihood: Strong

Lai Wang

Senior Vice President & Head of Global Research, Clinical Operation & Biometrics & Asia Pacific Clinical Development at BeiGene Ltd.

Relationship likelihood: Strong

Howard Liang

Chief Financial Officer & Chief Strategy Officer at BeiGene Ltd.

Relationship likelihood: Strong

Steven Young

Acting Head of Medicinal Chemistry at BeiGene Ltd.

Relationship likelihood: Strong

Scott Samuels

Secretary, General Counsel & Senior Vice President at BeiGene Ltd.

Relationship likelihood: Strong

Zhengming Du

Senior Vice President & Head of Chemistry & Manufacturing Controls at BeiGene Ltd.

Relationship likelihood: Strong

Jerry Zhang

Head of Finance at BeiGene Ltd.

Relationship likelihood: Strong

Wendy Yan

Senior Vice President, Global Head of Regulatory Affairs at BeiGene Ltd.

Relationship likelihood: Strong

Diana Lee Francis

Vice President & Global Head, Quality & Compliance at BeiGene Ltd.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

In The News

Business Wire

January 13, 2021

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

ENP Newswire

December 8, 2020

-BeiGene Announces the Approval in China of BLINCYTO for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

RelSci

August 8, 2020

Xiao Bin Wu sold $2.13M worth of shares in BeiGene Ltd. in July 2020

ENP Newswire

July 2, 2020

-BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

ENP Newswire

July 1, 2020

-BeiGene Begins Commercializing XGEVA in China

Paths to Xiao Bin Wu

Potential Connections via
Relationship Science

You

Xiao Bin Wu

General Manager, China & President at BeiGene Ltd.

Education

University of Konstanz

University of Konstanz provides top-class research, excellence in teaching and studies, inter-nationality and interdisciplinary cooperation.

Career History

Country Manager-China

Current

Pfizer Pharmaceuticals Ltd.

Pfizer Pharmaceuticals Ltd. is a pharmaceutical manufacturing company in China. It is a subsidiary compnay of Pfizer, Inc. The company was founded in 1980 and is headquartered in Beijing, CN.

General Manager, China & President

2018 - Current

BeiGene Ltd.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Public Holdings

Restricted data only for RelSci Professional users.

Other Affiliations

Xiao Bin Wu is affiliated with Pfizer Pharmaceuticals Ltd., BeiGene Ltd.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Xiao Bin Wu. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Xiao Bin Wu's profile does not indicate a business or promotional relationship of any kind between RelSci and Xiao Bin Wu.